Clinical Trial Update: RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of RO4929097 before surgery in pancreatic cancer was terminated. The study was sponsored by the National Cancer Institute.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer | Phase 1 | Status: TERMINATED